Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: PRL017
MIFTS: 45

Prolymphocytic Leukemia

Categories: Blood diseases, Cancer diseases
Genes Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Prolymphocytic Leukemia

About this section

MalaCards integrated aliases for Prolymphocytic Leukemia:

Name: Prolymphocytic Leukemia 12 75 15 72
Leukemia, Prolymphocytic 44
Leukemia Prolymphocytic 55

Classifications:

MalaCards categories:
Global: Cancer diseases
Anatomical: Blood diseases
See all MalaCards categories (disease lists)


External Ids:

Disease Ontology 12 DOID:1039
MeSH 44 D015463
NCIt 50 C3181
SNOMED-CT 68 10300002
UMLS 72 C0023486
Sources

Summaries for Prolymphocytic Leukemia

About this section
MalaCards based summary : Prolymphocytic Leukemia, also known as leukemia, prolymphocytic, is related to t-cell prolymphocytic leukemia and b cell prolymphocytic leukemia. An important gene associated with Prolymphocytic Leukemia is ATM (ATM Serine/Threonine Kinase), and among its related pathways/superpathways are PI3K-Akt signaling pathway and Cell cycle. The drugs Ketamine and Miconazole have been mentioned in the context of this disorder. Affiliated tissues include t cells, b cells and bone, and related phenotypes are cellular and hematopoietic system

Wikipedia : 75 Prolymphocytic leukemia is divided into two types according to the kind of cell involved: B-cell... more...

Sources

Related Diseases for Prolymphocytic Leukemia

About this section

Diseases related to Prolymphocytic Leukemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 170)
# Related Disease Score Top Affiliating Genes
1 t-cell prolymphocytic leukemia 34.4 TCL1A MYC MTCP1 ATM
2 b cell prolymphocytic leukemia 31.4 ZAP70 MYC FCER2 CD5 CD38 CD19
3 autoimmune lymphoproliferative syndrome, type v 30.7 TCL1A CD5
4 hairy cell leukemia 30.5 CD5 CCND1 ADA
5 lymphoma 30.3 TCL1A MYC CCND1 ATM
6 adult lymphoma 30.2 MYC CD5
7 richter's syndrome 29.9 MYC CD5 CD38 ATM
8 lymphocytic leukemia 29.6 ZAP70 MYC FCER2 CD5 CD38 ATM
9 anterior scleritis 29.5 CD5 CD19
10 lymphoma, mucosa-associated lymphoid type 29.1 CD5 CD19 CCND1
11 mantle cell lymphoma 28.9 MYC CD5 CD19 CCND1 ATM
12 cll/sll 28.8 ZAP70 CD5 CD38 CCND1 ATM
13 leukemia, chronic lymphocytic 27.0 ZAP70 TCL1A FCER2 CD5 CD38 CD19
14 lymphoma, non-hodgkin, familial 26.5 TCL1A MYC FCER2 CD5 CD38 CD19
15 splenic manifestation of prolymphocytic leukemia 12.4
16 leukemia 11.1
17 leukemia, b-cell, chronic 10.9
18 splenomegaly 10.8
19 t-cell leukemia 10.7
20 leukemia, t-cell, chronic 10.7
21 chromosomal triplication 10.6
22 lymphoproliferative syndrome 10.6
23 thrombocytopenia 10.4
24 ataxia-telangiectasia 10.4
25 telangiectasis 10.4
26 hematopoietic stem cell transplantation 10.4
27 ataxia and polyneuropathy, adult-onset 10.4
28 primary effusion lymphoma 10.4 TCL1A MYC
29 graft-versus-host disease 10.3
30 neutropenia 10.3
31 b-cell lymphoma 10.3
32 synchronous bilateral breast carcinoma 10.3 CCND1 ATM
33 exanthem 10.3
34 chromosome 8q duplication 10.3
35 adult t-cell leukemia 10.2
36 diffuse large b-cell lymphoma 10.2
37 purpura 10.2
38 hemolytic anemia 10.2
39 t-cell lymphoma 1a 10.2
40 chromosome 13q14 deletion syndrome 10.2 ZAP70 CD38
41 alk-negative anaplastic large cell lymphoma 10.2 MYC ADA
42 hemimegalencephaly 10.2 MYC CCND1
43 plasmablastic lymphoma 10.2 MYC CD38
44 cd45 deficiency 10.2 ZAP70 CD5
45 kaposi sarcoma 10.2
46 anemia, autoimmune hemolytic 10.2
47 leukemia, acute lymphoblastic 10.2
48 pancytopenia 10.2
49 acute leukemia 10.2
50 meningitis 10.2

Graphical network of the top 20 diseases related to Prolymphocytic Leukemia:



Diseases related to Prolymphocytic Leukemia
Sources

Symptoms & Phenotypes for Prolymphocytic Leukemia

About this section

MGI Mouse Phenotypes related to Prolymphocytic Leukemia:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.09 ABCB4 ADA ATM CCND1 CD19 CD38
2 hematopoietic system MP:0005397 10.02 ABCB4 ADA ATM CCND1 CD19 CD38
3 immune system MP:0005387 9.96 ABCB4 ADA ATM CCND1 CD19 CD38
4 endocrine/exocrine gland MP:0005379 9.91 ABCB4 ADA ATM CCND1 CD38 MYC
5 digestive/alimentary MP:0005381 9.88 ABCB4 ADA CCND1 CD19 FCER2 MYC
6 integument MP:0010771 9.63 ATM CCND1 CD19 CD5 MYC ZAP70
7 neoplasm MP:0002006 9.35 ABCB4 ATM CCND1 CD19 MYC
8 normal MP:0002873 9.1 ADA CCND1 CD19 CD5 MYC ZAP70
Sources

Drugs & Therapeutics for Prolymphocytic Leukemia

About this section

Drugs for Prolymphocytic Leukemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 254)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
2
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
3
Ondansetron Approved Phase 3 99614-02-5 4595
4
Darbepoetin alfa Approved, Investigational Phase 3 11096-26-7, 209810-58-2
5
Caspofungin Approved Phase 3 179463-17-3, 162808-62-0 468682 2826718
6
Heparin Approved, Investigational Phase 3 9005-49-6 46507594 772
7
Cladribine Approved, Investigational Phase 3 4291-63-8 20279
8
Guaifenesin Approved, Investigational, Vet_approved Phase 3 93-14-1 3516
9
Morphine Approved, Investigational Phase 3 57-27-2 5288826
10
Dalteparin Approved Phase 3 9005-49-6
11
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
12
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
13
Amphotericin B Approved, Investigational Phase 3 1397-89-3 14956 5280965
14
Cyclophosphamide Approved, Investigational Phase 2, Phase 3 50-18-0, 6055-19-2 2907
15
Busulfan Approved, Investigational Phase 2, Phase 3 55-98-1 2478
16
Etoposide Approved Phase 2, Phase 3 33419-42-0 36462
17
Melphalan Approved Phase 2, Phase 3 148-82-3 460612 4053
18
Thiotepa Approved, Investigational Phase 2, Phase 3 52-24-4 5453
19
Carboplatin Approved Phase 2, Phase 3 41575-94-4 10339178 498142 38904
20
Ginseng Approved, Investigational, Nutraceutical Phase 3 50647-08-0
21 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
22 Anesthetics, Dissociative Phase 3
23 Anti-Infective Agents Phase 3
24 Anti-Bacterial Agents Phase 3
25 Dermatologic Agents Phase 3
26 Antifungal Agents Phase 3
27 Analgesics Phase 3
28 Peripheral Nervous System Agents Phase 3
29 Cola Phase 3
30 Antiemetics Phase 3
31 Gastrointestinal Agents Phase 3
32 Autonomic Agents Phase 3
33 Psychotropic Drugs Phase 3
34 Neurotransmitter Agents Phase 3
35 Tranquilizing Agents Phase 3
36 Central Nervous System Depressants Phase 3
37 Anti-Anxiety Agents Phase 3
38 Serotonin Antagonists Phase 3
39 Analgesics, Opioid Phase 3
40 Serotonin Agents Phase 3
41 Antipruritics Phase 3
42 Antipsychotic Agents Phase 3
43 Hematinics Phase 3
44 Epoetin alfa Phase 3 113427-24-0
45 Fibrinolytic Agents Phase 3
46 calcium heparin Phase 3
47 Liver Extracts Phase 3
48 Narcotics Phase 3
49 Respiratory System Agents Phase 3
50 Chlorpheniramine, phenylpropanolamine drug combination Phase 3

Interventional clinical trials:

(show top 50) (show all 196)
# Name Status NCT ID Phase Drugs
1 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
2 A Randomized, Open-Label, Multicenter Study Of Darbepoetin Alfa Administered Once Every Two Weeks (Q2W) Compared With rHuEPO Administered Once Every Week (QW) For The Treatment Of Anemia In Subjects With Non-Myeloid Malignancies Receiving Multiple Chemotherapy Completed NCT00070382 Phase 3 darbepoetin alfa;epoetin alfa
3 A Randomized Phase III Study to Determine the Most Promising Postgrafting Immunosuppression for Prevention of Acute GVHD After Unrelated Donor Hematopoietic Cell Transplantation Using Nonmyeloablative Conditioning for Patients With Hematologic Malignancies: A Multi-center Trial Completed NCT01231412 Phase 3 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
4 Daily Versus Weekly Administration of 2-Chlorodeoxyadenosine (CDA) in Patients With Hairy Cell Leukemia Completed NCT00003746 Phase 3 2-chlorodeoxyadenosine (CDA) daily;2-chlorodeoxyadenosine weekly
5 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
6 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
7 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
8 A Phase III, Randomized Study of the Effects of Parenteral Iron, Oral Iron, or No Iron Supplementation on the Erythropoietic Response to Darbepoetin Alfa for Cancer Patients With Chemotherapy-Associated Anemia Completed NCT00661999 Phase 3 sodium ferric gluconate complex in sucrose
9 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
10 The Use of American Ginseng (Panax Quinquefolius) to Improve Cancer-Related Fatigue: A Randomized, Double-Blind, Placebo-Controlled Phase III Study Completed NCT00719563 Phase 3 American ginseng
11 Phase III Randomized Trial of an Opioid Titration Order Sheet Compared to Standard of Care in Patients With Cancer Related Pain. Completed NCT00666211 Phase 3
12 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
13 A Strategic Study to Determine the Optimal Moment to Initiate Systemic Antifungal Therapy With Ambisome in Granulocytopenic Cancer Patients With Unexplained Fever Refractory to Empirical Antibacterials Completed NCT00003938 Phase 3 liposomal amphotericin B
14 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
15 Allogeneic Blood or Marrow Transplantation for Hematologic Malignancy and Aplastic Anemia Active, not recruiting NCT00003816 Phase 2, Phase 3 busulfan;carboplatin;cyclophosphamide;etoposide;fludarabine phosphate;melphalan;thiotepa
16 Chimeric Antigen Receptor-Modified pNK Cells for CD7 Positive Relapsed or Refractory Leukemia and Lymphoma Unknown status NCT02742727 Phase 1, Phase 2
17 Pilot Study of Redirected Autologous T Cells Transduced to Express A CD20-Specific Chimeric Immunoreceptor in Patient With Chemotherapy Resistant or Refractory CD20+ Leukemia and Lymphoma Unknown status NCT01735604 Phase 1, Phase 2
18 A Pilot Study to Assess the Feasibility of Unrelated Umbilical Cord Blood Transplantation With Coinfusion of Third-party Mesenchymal Stem Cells After Myeloablative or Nonmyeloablative Conditioning in Patients With Hematological Malignancies Unknown status NCT01092026 Phase 1, Phase 2
19 Allogeneic Hematopoietic Stem Cell Transplantation With Nonmyeloablative Conditioning for Patients With Chronic Lymphocytic Leukemia - A Multi-center Trial Completed NCT00060424 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
20 Phase 1b/2 Study of Dinaciclib (SCH 727965) and Ofatumumab in Relapsed and Refractory CLL/SLL/B-PLL Completed NCT01515176 Phase 1, Phase 2 Dinaciclib
21 Phase II Trial of Combined Immunochemotherapy With Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab (FMC-Alemtuzumab) in Patients With Previously Treated or Untreated T-Prolymphocytic Leukemia Completed NCT01186640 Phase 2 Fludarabine, Mitoxantrone, Cyclophosphamide and Alemtuzumab;Alemtuzumab
22 Consolidation With Campath-1H After FMC Induction in Patients With T-cell Chronic Lymphocytic Leukemia Completed NCT00278213 Phase 2 cyclophosphamide;fludarabine phosphate;mitoxantrone hydrochloride
23 A Multicenter, Open-label, Single Arm Study of Weekly Alvocidib in Patients With Previously Treated B-Cell Chronic Lymphocytic Leukemia (CLL) or Prolymphocytic Leukemia (PLL) Arising From CLL Completed NCT00464633 Phase 2 alvocidib
24 A Phase II Trial of Post-Transplant Cyclophosphamide and Sirolimus for Graft-versus-host Disease (GVHD) Prophylaxis Following Reduced Intensity Allogeneic Hematopoietic Stem Cell Transplantation Completed NCT01244906 Phase 2
25 Minimal Ablation and Cellular Immune Therapy of Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, Low-Grade Non-Hodgkin's Lymphoma, and Mantle Cell Lymphoma With Allogeneic Donor Stem Cells Completed NCT00006252 Phase 2 fludarabine phosphate;Cyclophosphamide;G-CSF
26 Sequential Autologous HCT / Nonmyeloablative Allogeneic HCT Using Related, HLA-Haploidentical Donors for Patients With High-Risk Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia Completed NCT01008462 Phase 2 Carmustine;Cyclophosphamide;Cytarabine;Etoposide;Fludarabine Phosphate;Melphalan;Mycophenolate Mofetil;Tacrolimus
27 A Phase I Phase II Two-Step Study of the Oral Gold Compound Auranofin in Chronic Lymphocytic Leukemia (CLL)/ Small Lymphocytic Lymphoma (SLL)/ Prolymphocytic Lymphoma (PLL) Completed NCT01419691 Phase 2 auranofin
28 Umbilical Cord Blood (UCB) Allogeneic Stem Cell Transplant for Hematologic Malignancies Completed NCT01093586 Phase 2 busulfan;cyclophosphamide;anti-thymocyte globulin;methylprednisolone;cyclosporine;mycophenolate mofetil
29 A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia or Refractory/Relapsed B-Cell Chronic Lymphocytic Leukemia Completed NCT00452374 Phase 1, Phase 2 Cytarabine;Fludarabine;Oxaliplatin;Rituximab
30 A Phase I-II Study of Oxaliplatin, Fludarabine, Cytarabine, and Rituximab in Patients With Richter's Transformation, Prolymphocytic Leukemia, Aggressive, Relapsed or Refractory B-Cell Chronic Lymphocytic Leukemia Completed NCT00472849 Phase 1, Phase 2 Oxaliplatin;Fludarabine;Cytarabine;Rituximab;Pegfilgrastim
31 Assessment of Early and Standard Intervention With Procrit® (Epoetin Alfa) 120,000 Units Once Every Three Weeks (Q3W) in Patients With Cancer Receiving Chemotherapy Completed NCT00255749 Phase 2
32 Nonmyeloablative Conditioning With Pre- and Post-Transplant Rituximab Followed by Related or Unrelated Donor Hematopoietic Cell Transplantation for Patients With Advanced Chronic Lymphocytic Leukemia: A Multi-Center Trial Completed NCT00104858 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil
33 Non-Myeloablative Allogeneic Hematopoietic Cell Transplantation For Patients With Disease Relapse Or Myelodysplasia After Prior Autologous Transplantation Completed NCT00053196 Phase 2 busulfan;fludarabine phosphate;methotrexate;mycophenolate mofetil;tacrolimus;allopurinol
34 Phase I/II Study of Subcutaneously Administered Veltuzumab (hA20) in Patients With CD20+ Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia Completed NCT00546793 Phase 1, Phase 2
35 A Multicenter, Open, Phase II Study to Estimate the Activity and Safety of Caspofungin (CASP) in the First-Line Treatment of Probable and Proven Invasive Aspergillosis (IA) in Patients With Hematological Malignancies (HM) or Recipients of Autologous Haematopoietic Stem Cell Transplantation and Those With Allogeneic Haematopoietic Stem Cell Transplantation (HSCT) Completed NCT00110045 Phase 2 caspofungin acetate
36 A Phase II Study to Assess Immunosuppression With Sirolimus Combined With Cyclosporine (CSP) and Mycophenolate Mofetil (MMF) for Prevention of Acute GVHD After Non-Myeloablative HLA Class I or II Mismatched Donor Hematopoietic Cell Transplantation- A Multi-Center Trial Completed NCT01251575 Phase 2 Cyclosporine;Fludarabine Phosphate;Mycophenolate Mofetil;Sirolimus
37 Trial of Immune Reconstitution With Activated T-Cells in Patients With Chronic Lymphocytic Leukemia (CLL) Completed NCT02530515 Phase 2
38 An Open-label, Phase 1b/2, Safety and Efficacy Study of the Bruton's Tyrosine Kinase (Btk) Inhibitor, PCI-32765, and Ofatumumab in Subjects With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and Prolymphocytic Leukemia Completed NCT01217749 Phase 1, Phase 2 PCI-32765;ofatumumab
39 Phase II Trial With Correlative Laboratory Studies of Single Agent Irinotecan (Camptosar CPT-11) in Newly Diagnosed and Relapsed Indolent Lymphoproliferative Malignancies Completed NCT00005626 Phase 2 Irinotecan
40 Therapy of Chronic Lymphocytic Leukemia With Dasatinib (BMS-354825) Completed NCT00364286 Phase 2 Dasatinib (BMS-354825)
41 Phase II Study of High Dose Cyclophosphamide and Rituximab in Low Grade and Mantle Cell Lymphoma Completed NCT00278161 Phase 2 Cyclophosphamide
42 OUTPATIENT SUBCUTANEOUS IL-2 AND ALPHA INTERFERON IN THE MANAGEMENT OF METASTATIC CANCER Completed NCT00002504 Phase 2
43 Low Intensity Preparative Regimen Followed by HLA-Matched, Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Hematologic Malignancies in Older Adults Completed NCT00001637 Phase 2
44 Donor NK Cell Infusion for Progression/Recurrence of Underlying Malignant Disorders After HLA-haploidentical HCT - a Phase 1-2 Study Completed NCT00823524 Phase 1, Phase 2
45 A Phase II Trial of Myeloablative Conditioning and Transplantation of Partially HLA-Mismatched Peripheral Blood Stem Cells for Patients With Hematologic Malignancies Completed NCT00782379 Phase 2 busulfan;cyclophosphamide;fludarabine phosphate;mycophenolate mofetil;tacrolimus
46 Oral Beclomethasone Dipropionate Capsules for Treatment of Intestinal Graft-Versus-Host Disease: Compassionate Use in Patients With Contraindictions to High-Dose Immunosuppressive Therapy Completed NCT00010283 Phase 1, Phase 2 beclomethasone dipropionate
47 Purine-Analog-Containing Non-Myeloablative Allogeneic Stem Cell Transplantation for Treatment of Hematologic Malignancies and Severe Aplastic Anemia Completed NCT00006379 Phase 2 cyclophosphamide;fludarabine phosphate
48 A Phase II Clinical Trial of Anti-Tac(Fv)-PE38 (LMB-2) Immunotoxin for Treatment of CD25 Positive Chronic Lymphocytic Leukemia Completed NCT00077922 Phase 2 LMB-2
49 Treatment of Patients With Hematological Malignancies Using Marrow Transplantation From Unrelated Donors Incompatible for One HLA Locus Antigen Completed NCT00005804 Phase 2 cyclophosphamide
50 A Phase I-II Intensive-Dose Ifosfamide, Carboplatin and Taxotere (IC-T) Combination Chemotherapy Followed by Autologous Stem Cell Rescue for Patients With Refractory Malignancies Completed NCT00003406 Phase 1, Phase 2 carboplatin;docetaxel;ifosfamide

Search NIH Clinical Center for Prolymphocytic Leukemia

Cochrane evidence based reviews: leukemia, prolymphocytic

Sources

Genetic Tests for Prolymphocytic Leukemia

About this section
Sources

Anatomical Context for Prolymphocytic Leukemia

About this section

MalaCards organs/tissues related to Prolymphocytic Leukemia:

41
T Cells, B Cells, Bone, Bone Marrow, Myeloid, Nk Cells, Liver
Sources

Publications for Prolymphocytic Leukemia

About this section

Articles related to Prolymphocytic Leukemia:

(show top 50) (show all 803)
# Title Authors PMID Year
1
[CD5-positive B-cell prolymphocytic leukemia]. 9 38
20134145 2010
2
Molecular allelokaryotyping of T-cell prolymphocytic leukemia cells with high density single nucleotide polymorphism arrays identifies novel common genomic lesions and acquired uniparental disomy. 9 38
19278963 2009
3
Haploinsufficiency of CDKN1B contributes to leukemogenesis in T-cell prolymphocytic leukemia. 9 38
18073348 2008
4
High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemia. 9 38
17890451 2008
5
IgVH genes mutation and usage, ZAP-70 and CD38 expression provide new insights on B-cell prolymphocytic leukemia (B-PLL). 9 38
16642047 2006
6
D cyclins in CD5+ B-cell lymphoproliferative disorders: cyclin D1 and cyclin D2 identify diagnostic groups and cyclin D1 correlates with ZAP-70 expression in chronic lymphocytic leukemia. 9 38
16393687 2006
7
Inhibition of Akt kinase activity by a peptide spanning the betaA strand of the proto-oncogene TCL1. 9 38
15459205 2004
8
Immunohistochemical detection of ZAP-70 in 341 cases of non-Hodgkin and Hodgkin lymphoma. 9 38
15133473 2004
9
ATM mutations are associated with inactivation of the ARF-TP53 tumor suppressor pathway in diffuse large B-cell lymphoma. 9 38
12149228 2002
10
Breakpoints in the ataxia telangiectasia gene arise at the RGYW somatic hypermutation motif. 9 38
11821961 2002
11
Structure of murine Tcl1 at 2.5 A resolution and implications for the TCL oncogene family. 9 38
11679718 2001
12
TCL1 is activated by chromosomal rearrangement or by hypomethylation. 9 38
11241786 2001
13
Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues. 9 38
10786666 2000
14
Aberrant splicing of the ATM gene associated with shortening of the intronic mononucleotide tract in human colon tumor cell lines: a novel mutation target of microsatellite instability. 9 38
10738255 2000
15
Role of TCL1 and ALL1 in human leukemias and development. 9 38
10197596 1999
16
Transgenic mice for MTCP1 develop T-cell prolymphocytic leukemia. 9 38
9657733 1998
17
Ataxia-telangiectasia and T-cell leukemias: no evidence for somatic ATM mutation in sporadic T-ALL or for hypermethylation of the ATM-NPAT/E14 bidirectional promoter in T-PLL. 9 38
9622061 1998
18
Inactivation of the ATM gene in T-cell prolymphocytic leukemias. 9 38
9573030 1998
19
Solution structure of the recombinant human oncoprotein p13MTCP1. 9 38
9691281 1998
20
Crystal structure of p14TCL1, an oncogene product involved in T-cell prolymphocytic leukemia, reveals a novel beta-barrel topology. 9 38
9519406 1998
21
Alternative origin of p13MTCP1-encoding transcripts in mature T-cell proliferations with t(X;14) translocations. 9 38
9315101 1997
22
Perforin-positive leukemic cell infiltration in the aortic tissue of a patient with T-cell prolymphocytic leukemia. 9 38
8971584 1996
23
Expression of p13MTCP1 is restricted to mature T-cell proliferations with t(X;14) translocations. 9 38
8634440 1996
24
Overexpression of the PRAD1 oncogene in a patient with prolymphocytic leukemia with t(11;14)(q13;q32). 9 38
7497446 1995
25
B-cell prolymphocytic leukemia expressing CD13 antigen. 9 38
7524729 1994
26
Burkitt-like mutations in the c-myc gene locus in prolymphocytic leukemia. 9 38
8182948 1994
27
Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. 9 38
8172823 1994
28
Induction of apoptosis in CD4+ prolymphocytic leukemia by deoxyadenosine and 2'-deoxycoformycin. 9 38
1528066 1992
29
Expression of the mdr3 gene in prolymphocytic leukemia: association with cyclosporin-A-induced increase in drug accumulation. 9 38
2323839 1990
30
Purine metabolism enzymes and immunological phenotype in chronic B-cell malignancies: chronic lymphocytic leukemia, prolymphocytic leukemia and hairy cell leukemia. 9 38
2125699 1990
31
Effect of allogeneic hematopoietic cell transplantation for patients with T-prolymphocytic leukemia: a retrospective study from the Adult Lymphoma Working Group of the Japan Society for hematopoietic cell transplantation. 38
31327025 2019
32
Sensitizing the interdisciplinary team to desensitizations: An alemtuzumab case report. 38
31390960 2019
33
CD161 Is Expressed in a Subset of T-Cell Prolymphocytic Leukemia Cases and Is Useful for Disease Follow-up. 38
31305900 2019
34
Combined use of tofacitinib (pan-JAK inhibitor) and ruxolitinib (a JAK1/2 inhibitor) for refractory T-cell prolymphocytic leukemia (T-PLL) with a JAK3 mutation. 38
30997845 2019
35
Post-transplant lymphoproliferative disorder presenting as T-prolymphocytic leukemia: a case report. 38
31327318 2019
36
Consensus criteria for diagnosis, staging, and treatment response assessment of T-cell prolymphocytic leukemia (T-PLL). 38
31292114 2019
37
T-cell prolymphocytic leukemia presenting as ascites. 38
31345928 2019
38
Cytoplasmic Blebs in T-Cell Prolymphocytic Leukemia. 38
31189039 2019
39
[Successful Treatment of T-Cell Prolymphocytic Leukemia with Alemtuzumab]. 38
31189814 2019
40
[High-dose methylprednisolone with Rituximab and fresh frozen plasma in the treatment of six patients with B-cell lymphoproliferative disorders harboring TP53 abnormalities]. 38
31207703 2019
41
Where do we currently stand with T-cell prolymphocytic leukemia? 38
30668215 2019
42
New lessons learned in T-PLL: results from a prospective phase-II trial with fludarabine-mitoxantrone-cyclophosphamide-alemtuzumab induction followed by alemtuzumab maintenance. 38
30234404 2019
43
Clinically silent indolent T-cell leukemia. 38
30656001 2019
44
EBMT prospective observational study on allogeneic hematopoietic stem cell transplantation in T-prolymphocytic leukemia (T-PLL). 38
30664723 2019
45
Papuloerythroderma-like cutaneous involvement of a CD62L- subclone of T-cell prolymphocytic leukemia. 38
30450688 2019
46
Hot and Cold: A Concurrent Warm and Cold Autoimmune Hemolytic Anemia in B-cell Prolymphocytic Leukemia. 38
30947164 2019
47
Composite Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma and T-Prolymphocytic Leukemia Presenting with Lymphocytosis, Skin Lesions, and Generalized Lymphadenopathy. 38
30941227 2019
48
False-Positive Light Chain Clonal Restriction by Flow Cytometry in Patients Treated With Alemtuzumab: Potential Pitfalls for the Misdiagnosis of B-Cell Neoplasms. 38
30307483 2019
49
Small cell variant of T-cell prolymphocytic leukemia with atypical presentation. 38
30588459 2018
50
Next-generation amplicon TRB locus sequencing can overcome limitations of flow-cytometric Vβ expression analysis and confirms clonality in all T-cell prolymphocytic leukemia cases. 38
30414304 2018
Sources

Variations for Prolymphocytic Leukemia

About this section
Sources

Expression for Prolymphocytic Leukemia

About this section
Search GEO for disease gene expression data for Prolymphocytic Leukemia.
Sources

Pathways for Prolymphocytic Leukemia

About this section

Pathways related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 19)
# Super pathways Score Top Affiliating Genes
1
PI3K-Akt signaling pathway 37
Show member pathways
 12.47 TCL1A MYC MTCP1 CD19 CCND1 ATM
2
Cell cycle 1 37
12.12 MYC CCND1 ATM
3
Cellular senescence (KEGG) 37
11.92 MYC CCND1 ATM
4
Integrated Breast Cancer Pathway 1
11.87 MYC CCND1 ATM
5
Hematopoietic Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.74 CD5 CD38 CD19
6
DNA Damage Response (only ATM dependent) 1
11.71 MYC CCND1 ATM
7
Interleukin-4 and 13 signaling 66
11.69 MYC FCER2 CCND1
8
C-MYB transcription factor network 1
11.5 MYC CCND1 ADA
9
Regulation of Telomerase 1
11.4 MYC CCND1 ATM
10
miRNAs involved in DNA damage response 1
11.24 MYC CCND1 ATM
11
Hematopoietic cell lineage 37
11.24 FCER2 CD5 CD38 CD19
12
FOXM1 transcription factor network 1
11.14 MYC CCND1
13
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.14 MYC CCND1 ATM
14
IL-10 Pathway 64
11.11 MYC CCND1
15
GADD45 Pathway 64
11.06 CCND1 ATM
16
Primary immunodeficiency 37
11 ZAP70 CD19 ADA
17
PPAR Alpha Pathway 1
10.96 MYC CCND1
18
TP53 Network 1
Show member pathways
 10.87 MYC ATM
19
B Cell Development Pathways 65
10.65 FCER2 CD5 CD38 CD19
Sources

GO Terms for Prolymphocytic Leukemia

About this section

Cellular components related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 external side of plasma membrane GO:0009897 8.92 FCER2 CD5 CD19 ADA

Biological processes related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

(show all 13)
# Name GO ID Score Top Affiliating Genes
1 negative regulation of apoptotic process GO:0043066 9.81 TCL1A MYC CD38 ADA
2 positive regulation of cell proliferation GO:0008284 9.8 TCL1A MYC CD38 CCND1
3 response to hypoxia GO:0001666 9.65 CD38 ATM ADA
4 response to estradiol GO:0032355 9.58 MYC CD38 CCND1
5 liver regeneration GO:0097421 9.52 MYC CCND1
6 positive regulation of T cell differentiation GO:0045582 9.46 ZAP70 ADA
7 positive regulation of calcium-mediated signaling GO:0050850 9.43 ZAP70 ADA
8 positive regulation of response to DNA damage stimulus GO:2001022 9.37 MYC ATM
9 positive regulation of mitochondrial membrane potential GO:0010918 9.32 TCL1A MYC
10 positive regulation of alpha-beta T cell differentiation GO:0046638 9.26 ZAP70 ADA
11 response to vitamin E GO:0033197 9.16 CCND1 ADA
12 re-entry into mitotic cell cycle GO:0000320 8.96 MYC CCND1
13 response to drug GO:0042493 8.92 MYC CD38 CCND1 ADA

Molecular functions related to Prolymphocytic Leukemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein serine/threonine kinase activator activity GO:0043539 8.62 TCL1A MTCP1
Sources

Sources for Prolymphocytic Leukemia

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 TGDB
71 Tocris
72 UMLS
73 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....